annb0t
Top 20
Mesoblast Limited
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its allogeneic âoff-the-shelfâ product candidate for the treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF), will be highlighted in a panel discussion titled âLate-Stage Advancements in Heart Failure Therapeutics and Managementâ, pre...
>>> Read more: Rexlemestrocel-L to be Highlighted at Maximâs Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its allogeneic âoff-the-shelfâ product candidate for the treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF), will be highlighted in a panel discussion titled âLate-Stage Advancements in Heart Failure Therapeutics and Managementâ, pre...
>>> Read more: Rexlemestrocel-L to be Highlighted at Maximâs Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
